Linaclotide in chronic idiopathic constipation patients with moderate to severe abdominal bloating: A randomized, controlled trial

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Lacy, Brian E ^a   Schey, Ron ^b   Shiff, Steven J ^c   Lavins, Bernard J ^c   Fox, Susan M ^c   Jia, Xinwei D ^c   Blakesley, Rick E ^c   Hao, Xinming ^c   Cronin, Jacquelyn A ^c   Currie, Mark G ^c   Kurtz, Caroline B ^c   Johnston, Jeffrey M ^c   Lembo, Anthony J ^d  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c Forest Laboratories LLC Actavis plc ^*  (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GASTROINTESTINAL AGENT; LINACLOTIDE; PEPTIDE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; CHRONIC DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; CONSTIPATION; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; MALE; MIDDLE AGED; PEPTIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84942016264     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0134349     Document Type: Article

References (32)

1. Higgins PD, Johanson JF. Epidemiology of constipation in North America: A systematic review. Am J Gastroenterol 2004; 99(4):750-9. PMID: 15089911.
2. Sandler RS, Drossman DA. Bowel habits in young adults not seeking health care. Dig Dis Sci 1987; 32 (8):841-5. PMID: 3608732.
3. Koch A, Voderholzer WA, Klauser AG, Muller-Lissner S. Symptoms in chronic constipation. Dis Colon Rectum 1997; 40(8):902-6. PMID: 9269805.
4. Johanson JF, Kralstein J. Chronic constipation: A survey of the patient perspective. Aliment Pharmacol Ther 2007; 25(5):599-608. PMID: 17305761.
5. Lacy BE, Gabbard SL, Crowell MD. Pathophysiology, evaluation, and treatment of bloating: hope, hype, or hot air? Gastroenterol Hepatol 2011; 7(11):729-39.
6. Houghton LA. Bloating in constipation: Relevance of intraluminal gas handling. Best Pract Res Clin Gastroenterol 2011; 25:141-50. doi:10.1016/j.bpg.2010.12.009 PMID: 21382585.
7. Jiang X, Locke GR, Choung RS, Zinsmeister AR, Schleck CD, Talley NJ. Prevalence and risk factors for abdominal bloating and visible distention: A population-based study. Gut 2008; 57:756-63. doi:10.1136/gut.2007.142810PMID: 18477677.
8. Seo AY, Kim N, Oh DH. Abdominal bloating: Pathophysiology and treatment. J Neurogastroenterol Motil 2013; 19:433-53. doi:10.5056/jnm.2013.19.4.433 PMID: 24199004.
9. Villoria A, Azpiroz F, Burri E, Cisternas D, Soldevilla A, Malagelada JR. Abdomino-phrenic dyssynergia in patients with abdominal bloating and distension. Am J Gastroenterol 2011; 106:815-9. doi:10.1038/ajg.2010.408 PMID: 21540894.
10. Gudsoorkar VS, Quigley EM. Emerging treatments for chronic constipation. Expert Opin Emerg Drugs 2013; 18:365-73. doi:10.1517/14728214.2013.831068 PMID: 23957819.
11. Singh S, Rao SS. Pharmacologic management of chronic constipation. Gastroenterol Clin North Am 2010; 39:509-27. doi:10.1016/j.gtc.2010.08.001 PMID: 20951915.
12. Bryant AP, Busby RW, Bartolini WP, Cordero EA, Hannig G, Kessler MM, et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci 2010; 86:760-5. doi:10.1016/j.lfs.2010.03.015 PMID: 20307554.
13. Busby RW, Bryant AP, Bartolini WP, Cordero EA, Hannig G, Kessler MM, et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol 2010; 649:328-35. doi:10.1016/j.ejphar.2010.09.019 PMID: 20863829.
14. Busby RW, Kessler MM, Bartolini WP, Bryant AP, Hannig G, Higgins CS, et al. Pharmacological properties, metabolism and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J Pharmacol Exp Ther 2013; 344:196-206. doi:10.1124/jpet.112.199430 PMID: 23090647.
15. Castro J, Harrington AM, Hughes PA, Martin CM, Ge P, Shea CM, et al. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic GMP. Gastroenterology 2013; 145(6):1334-46. doi:10.1053/j.gastro.2013.08.017 PMID: 23958540.
16. Eutamene H, Bradesi S, Larauche M, Theodorou V, Beaufrand C, Ohning G, et al. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil 2010; 22(3):312-22. doi:10.1111/j.1365-2982.2009.01385.x PMID: 19706070.
17. Silos-Santiago I, Hannig G, Eutamene H, Ustinova EE, Bernier SG, Ge P, et al. Gastrointestinal pain: Unraveling a novel endogenous pathway through uroguanylin/guanylate cyclase-C/cGMP activation. Pain 2013; 154:1820-30. PMID: 23748116.
18. Lembo AJ, Schneier HA, Shiff SJ, Kurtz CB, Macdougall JE, Jia XD, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011 Aug 11; 365(6):527-36. doi:10.1056/NEJMoa1010863PMID: 21830967.
19. Drossman DA, Corazziari E, Talley NJ, Thompson CA, Whitehead WE. Rome II: A multinational consensus document on functional gastrointestinal disorders. 45 ed. McLean, VA: Degnon Associates; 1999.
20. Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE. Chapter 7: Functional Bowel Disorders and Functional Abdominal Pain. ROME II: The Functional Gastrointestinal Disorders 2000;360-91.
21. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003; 124(2):544-60. PMID: 12557158.
22. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry: irritable bowel syndrome-clinical evaluation of drugs for treatment. 2012. Available: http://www.fda.gov/downloads/drugs/guidances/ucm205269.pdf.
23. Agrawal A, Houghton LA, Lea R, Morris J, Reilly B, Whorwell PJ. Bloating and distention in irritable bowel syndrome: The role of visceral sensation. Gastroenterology 2008; 134:1882-9. doi:10.1053/j.gastro.2008.02.096 PMID: 18455167.
24. Murray K, Wilkinson-Smith V, Hoad C, Costigan C, Cox E, Lam C, et al. Differential effects of FODMAPs (fermentable oligo-, di-, mono-saccharides and polyols) on small and large intestinal contents in healthy subjects shown by MRI. Am J Gastroenterol 2014; 109:110-9. doi:10.1038/ajg.2013.386PMID: 24247211.
25. Tremolaterra F, Villoria A, Azpiroz F, Serra J, Aguadé S, Malagelada JR. Impaired viscerosomatic reflexes and abdominal-wall dystony associated with bloating. Gastroenterology 2006; 130:1062-8. PMID: 16618400.
26. Shekhar C, Monaghan PJ, Morris J, Issa B, Whorwell PJ, Keevil B, et al. Rome III Functional constipation and irritable bowel syndrome with constipation are similar disorders within a spectrum of sensitization, regulated by serotonin. Gastroenterology 2013; 145(4):749-57. doi:10.1053/j.gastro.2013.07.014 PMID: 23872499.
27. Chang L, Lembo A, Sultan S. American gastroenterological association institute technical review on the pharmacological management of irritable bowel syndrome. Gastroenterology 2014; 147:1149-72. doi:10.1053/j.gastro.2014.09.002 PMID: 25224525.
28. Rey E, Balboa A, Mearin F. Chronic constipation, irritable bowel syndrome with constipation and constipation with pain/discomfort: similarities and differences. Am J Gastroenterol 2014.
29. Wong RK, Palsson OS, Turner MJ, Levy RL, Feld AD, von KM, et al. Inability of the Rome III criteria to distinguish functional constipation from constipation-subtype irritable bowel syndrome. Am J Gastroenterol 2010; 105:2228-34. doi:10.1038/ajg.2010.200PMID:20502449.
30. Chey WD, Lembo AJ, Lavins BJ, Shiff SJ, Kurtz CB, Currie MG, et al. Linaclotide for irritable bowel syndrome with constipation: A 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol 2012; 107:1702-12. PMID: 22986437.
31. Rao S, Lembo AJ, Shiff SJ, Lavins BJ, Currie MG, Jia XD, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol 2012; 107:1714-25. PMID: 22986440.
32. Farrar JT, Young JP, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001; 94:149-58. PMID: 11690728.